The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Feasibility Study on the Characterization of the Immune Profile of Young Patients After Treatment for Breast Cancer
Official Title: Feasibility Study on the Characterization of the Immune Profile of Young Patients After Treatment for Breast Cancer
Study ID: NCT04645849
Brief Summary: This study aim to determine kinetic of post treatment recovery/variation of a panel of innate and adaptative immune system cells and molecules. The results should allow to determine the optimal post treatment immunomonitoring timing and panel to be used for future studies.
Detailed Description: There is a complexe interaction between tumor cells ans host immunity. Immunity system (IS) is clearly involved in cancer developement control, and it is suggested that it could participate to the response to anti cancer treatment. There is however no validated immunomonitoring strategy to allow a reliable patient's immune status along time, and particularly after treatment.There are scarce existing information on immunologic reconstitution profile recovery after treatment. This study aim to perform immunomonitoring in young patients with cancer to describe kinetic of recovery/variation of a panel of innate and adaptative immune system cells and molecules, selected by their potential relevance according to literature. The concerned population are young women (˂40 yo) with breast cancer. There will be 2 patients cohorts A or "End of treatment" : patients recruited at the end of treatment (study cohort) B or "Diagnosis" : Patients recruited at diagnosis (reference values) This study should contribute to give sufficient data to determine the pertinent timing and cells/molecules panel to evaluate immunity profiling after treatment. These results could be used for further studies.
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: FEMALE
Healthy Volunteers: No
Chu Grenoble Alpes, Grenoble, , France
Name: Leila Gofti-Laroche, PharmD
Affiliation: University Hospital, Grenoble
Role: PRINCIPAL_INVESTIGATOR